These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33497951)

  • 1. Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.
    Bose G; Freedman MS
    J Neurol Sci; 2021 Feb; 421():117324. PubMed ID: 33497951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
    Bose G; Thebault S; Rush CA; Atkins HL; Freedman MS
    Mult Scler; 2021 Feb; 27(2):167-173. PubMed ID: 32364422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status.
    Mariottini A; De Matteis E; Muraro PA
    BioDrugs; 2020 Jun; 34(3):307-325. PubMed ID: 32166703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
    Willison AG; Meuth SG
    Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis.
    Mariottini A; Nozzoli C; Carli I; Landi F; Gigli V; Repice AM; Ipponi A; Cecchi M; Boncompagni R; Saccardi R; Massacesi L
    Neurol Sci; 2024 Jul; 45(7):3379-3387. PubMed ID: 38277051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
    Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
    Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' expectations of autologous hematopoietic stem cell transplantation as a treatment for MS.
    De Kleermaeker FGCM; Uitdehaag BMJ; van Oosten BW
    Mult Scler Relat Disord; 2020 Jan; 37():101467. PubMed ID: 31678857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis.
    Ross LA; Stropp LM; Cohen JA
    Neurol Clin; 2024 Feb; 42(1):165-184. PubMed ID: 37980114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation.
    Ismail A; Sharrack B; Saccardi R; Moore JJ; Snowden JA
    Curr Opin Support Palliat Care; 2019 Dec; 13(4):394-401. PubMed ID: 31599815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
    Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis.
    Kasarełło K; Snarski E; Sulejczak D; Ciesielski T; Wiśniewska A; Wrzesień R; Cudnoch-Jędrzejewska A
    Arch Immunol Ther Exp (Warsz); 2021 Jun; 69(1):17. PubMed ID: 34181099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
    Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
    Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol.
    Puyade M; Brunet F; Carolina R; Fergusson N; Makedonov I; Freedman MS; Atkins H
    Curr Protoc; 2022 May; 2(5):e437. PubMed ID: 35594180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.
    Orlewska K; Bogusz K; Podlecka-Piętowska A; Nojszewska M; Markiewicz M; Liwoch R; Orlewski P; Śliwczyński A; Zakrzewska-Pniewska B; Snarski E
    Value Health Reg Issues; 2021 Sep; 25():104-107. PubMed ID: 33865219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.
    Atkins HL; Freedman MS
    Neurotherapeutics; 2017 Oct; 14(4):888-893. PubMed ID: 28822119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
    Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Inflammatory and Neurodegenerative Biomarkers after Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.
    Ruder J; Dinner G; Maceski A; Berenjeno-Correa E; Müller AM; Jelcic I; Kuhle J; Martin R
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.
    Mariottini A; Marchi L; Innocenti C; Di Cristinzi M; Pasca M; Filippini S; Barilaro A; Mechi C; Fani A; Mazzanti B; Biagioli T; Materozzi F; Saccardi R; Massacesi L; Repice AM
    Front Neurol; 2022; 13():820256. PubMed ID: 35280289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.